Royalty Pharma (RPRX)

• Market cap: $17.8B
• 1 day: 2.01%
• 5 days: 3.14%
• 1 month: 6.9%
• 3 months: 12.83%
• 6 months: 12.28%
• Year to date: 7.26%
• 1 year: 31.94%
• 5 years: -10.81%
• 10 years: -6.34%
• Sector: Healthcare
• Industry: Biotechnology

About: Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.

Employees: 99